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Edge Vascular Response After Percutaneous
Coronary Intervention
An Intracoronary Ultrasound and Optical Coherence Tomography Appraisal:
From Radioactive Platforms to First- and Second-Generation Drug-Eluting Stents
and Bioresorbable Scaffolds
Bill D. Gogas, MD,*† Hector M. Garcia-Garcia, MD, MSC, PHD,* Yoshinobu Onuma, MD,*
akashi Muramatsu, MD, PHD,* Vasim Farooq, MBCHB,* Christos V. Bourantas, MD, PHD,*
atrick W. Serruys, MD, PHD*
Rotterdam, the Netherlands; and Atlanta, Georgia
The concept of edge vascular response (EVR) was ﬁrst introduced with bare-metal stents and later with
radioactive stents of various activity levels. Although radioactive stents reduced intra-stent neointimal
hyperplasia and thereby the incidence of in-stent restenosis in a dose-dependent manner, tissue prolif-
eration at the non-irradiated proximal and distal stent edges resulted in the failure of this invasive
treatment. The advent of ﬁrst- and second-generation drug-eluting stents (DES) reduced in-stent reste-
nosis to approximately 5% to 10%, depending on the lesion subset and DES type. When in-segment
restenosis (stent and 5-mm proximal and distal margins) occurred, it was most commonly focal and
located at the proximal edge. In addition, stent thrombosis, the other main contributing factor for DES
failure, seemed in part to be associated with residual plaque presence and underlying tissue composi-
tion at the landing zone of the implanted device, particularly if landed in a necrotic core rich milieu.
More recently, the introduction of bioresorbable scaffolds for the treatment of coronary artery disease
has prompted the re-evaluation of the EVR. This has recently been assessed up to 2-years after implan-
tation of the Absorb bioresorbable vascular scaffold (Abbott Vascular, Santa Clara, California). In gen-
eral, the EVR consists of a focal but signiﬁcant proximal lumen loss that in a few instances necessitates
target lesion revascularization of a ﬂow-limiting edge stenosis. Herein, we provide an overview of the
in vivo evaluation of the EVR with intravascular ultrasound, virtual histology intravascular ultrasound,
and the more recently developed optical coherence tomography. Our objective is to highlight the clin-
ical importance of the EVR as a predisposing and contributing factor to device failure with either bare-
metal stents, DES, or bioresorbable scaffolds. (J Am Coll Cardiol Intv 2013;6:211–21) © 2013 by the
American College of Cardiology FoundationThe use of metallic or bioresorbable devices for the
treatment of significant coronary artery disease
From the *Thoraxcenter, Erasmus University Medical Centre, Rotter-
dam, the Netherlands; and the †Andreas Gruentzig Cardiovascular
Center, Division of Cardiology, Department of Medicine, Emory
University, School of Medicine, Atlanta, Georgia. The authors have
reported that they have no relationships relevant to the contents of this
paper to disclose.Manuscript received September 25, 2012; revised manuscript received
January 24, 2013, accepted January 30, 2013.(CAD) has been proven to be a successful strategy
in the field of interventional cardiology; however,
the exuberant vascular responses resulting in either
in-segment restenosis or stent thrombosis (ST)
remain the cautionary tale of these technologies, as
previously reported by preclinical studies (1,2). The
pattern of vascular response after device implantation
manifests either as in-stent vascular response (focal or
diffuse) or as edge vascular response (EVR) at the
transition zones (focal)—each of which have impor-
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212tant prognostic implications (3). A significant response at the
proximal or distal edge can manifest as edge restenosis that
requires repeat revascularization or even vessel occlusion.
Previous pathological reports from the era of radioactive
stents have shown that the predominant tissue found at the
edges in the setting of an abnormal EVR consists of smooth
muscle cells in disarray and abundant extracellular matrix (4).
The EVR can be assessed clinically with quantitative
oronary angiography, intravascular ultrasound, or optical
oherence tomography (OCT). In this review, we focus on
he in vivo assessment with sound-based imaging modalities
fter implantation of metallic or bioresorbable devices and
further explore the feasibility to
assess the EVR with optical
technology (Fig. 1). Further-
more, the clinical implications of
the EVR are reported.
EVR in the Era of
Bare-Metal Stents and
Radioactive Platforms
Although balloon angioplasty was
undoubtedly a significant break-
through in the invasive treatment of
CAD, this mode of treatment was
plagued by several drawbacks, in-
cluding intimal and media dissec-
tions, acute vessel recoil or subacute
closure, late constrictive remodeling,
and a diffuse proliferative neointi-
mal response because of vascular
barotrauma (5). The advent of bare-
metal stents (BMS) and the land-
mark BENESTENT (BElgian-
NEtherlands STENT Study) (6)
and STRESS (STent REStenosis
Study) (7) trials were a significant
leap forward in CAD treatment, as
permanent metallic cages elimi-
nated the previously observed acute
vessel recoil/closure and scaffolded
he post-procedural dissection flaps observed with angio-
lasty. The EVR after BMS implantation was mainly
ttributed to plaque and media increase becoming more
vident at the region adjacent (1 to 2 mm) to the proximal
nd distal stent edges. At further distances (3 to 10 mm),
umen loss (LL) was primarily due to constrictive remodel-
ng (reduction of external elastic membrane [EEM]) rather
han to plaque and media increase (8). Furthermore, late
alapposition at BMS edges was evident in 4% to 5%,
ecause of expansive remodeling without increase in intimal
yperplasia (9). Although some degree of EVR was ob-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CAD  coronary artery
disease
DES  drug-eluting stent(s)
EEM  external elastic
membrane
EVR  edge vascular
response
FU  follow-up
GM  geographic miss
IVUS  intravascular
ultrasound
LL  lumen loss
OCT  optical coherence
tomography
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLR  target lesion
revascularization
VH-IVUS  virtual histology
intravascular ultrasound
ZES  zotarolimus-eluting
stent(s)erved with BMS, isolated margin re-narrowing, particu- rarly involving only the proximal and distal stent edges, was
n uncommon cause of stent failure in the BMS era (10).
Experimental endovascular delivery—either catheter-
ased or through irradiation-emitting metallic stent plat-
orms—of beta and gamma radiation initially proved to be
feasible and efficacious method to inhibit neointimal cell
roliferation with significant reductions in restenosis rates
n animal models (11–14).
The clinical validation of the catheter-based endovascular
adiation delivery proved to be safe and feasible in the
rst-in-man studies (15–17).
Irradiation-emitting stent platforms (with various activity
evels) were conceived as a more practical way to overcome
he problem of neointimal hyperplasia associated with
MS. The Milan Dose-Response Study proved the feasi-
ility of the 32P radioactive beta-emitting stent (3.0 and 12
Ci) in completely inhibiting in-stent neointimal hyperpla-
sia (3 Ci). Despite these promising findings, the tech-
nology was offset by an increased late LL and restenosis
adjacent to the proximal and distal edges of the implanted
device, dubbed the edge effect or “candy-wrapper” phenom-
enon (18). The edge effect was defined angiographically at
follow-up (FU) as a diameter stenosis at the proximal and
distal stent edges of 50%. Bench studies investigating the
pathogenesis of this effect incriminated the combination of
radioactive dose fall-off at the transition zones (stent edges)
in association with the peri-procedural geographic miss
(GM) phenomenon (11). The GM (axial or longitudinal) is
essentially the failure of the device to appropriately scaffold
a balloon-injured vessel (e.g., under-expansion of stent/axial
GM) or to completely cover the vessel wall (diseased or not)
that had been previously baro-traumatized by balloon pre-
dilation, which can result from an overhanging balloon
during stent deployment or by balloon post-dilation (longi-
tudinal GM) (19,20). Although various modifications of the
existing technologies were proposed to overcome the limi-
tation of EVR (21)—such as the square-shouldered balloon,
the hybrid radioactive stent, the self-expanding radioactive
stent, the cold-end stent, the hot-end stent—radioactive plat-
forms failed as an interventional technique and were replaced
by the next endeavor in interventional cardiology, the DES.
EVR With Drug-Eluting Metallic Platforms
First-generation DES. SIROLIMUS-ELUTING METALLIC PLAT-
FORM. The RAVEL trial (RAndomized study with the
irolimus-eluting VElocity balloon-expandable stent in the
reatment of patients with de novo native coronary artery
esions) was the first randomized double-blind study to
stablish the angiographic superiority of DES (sirolimus-
luting Bx Velocity balloon expandable stent [SES] [Cordis,
ohnson and Johnson, Miami, Florida] over a BMS (Bx.
elocity balloon expandable stent). The EVR at 6 monthsevealed no significant LL at the proximal or distal SES
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213edges; however, a nonsignificant lumen gain at the distal
edge of 0.09  0.30 mm was present (22–24). Notably, the
RAVEL trial was performed in noncomplex coronary le-
sions with an average stent length/lesion length ratio of
approximately 2, and a nonaggressive implantation strategy
was undertaken that involved pre-dilation of the stent
landing zone located in angiographically normal segments.
These favorable but artificial circumstances of implantation
did not represent the real-world practice and might poten-
tially explain the neutral EVR after SES implantation in
this first pivotal trial.
Subsequently, the SIRIUS trials (multicenter, random-
ized, double-blind trial of the SIRolImUS-coated Bx-
Velocity stent in the treatment of patients with de novo
coronary artery lesions) (SIRIUS-US and E-SIRIUS) com-
pared SES versus BMS in more complex lesions (long
lesions, small vessels).
The SIRIUS-US trial showed a rate of angiographic
in-segment restenosis of 8.9%, which was a result of
excessive neointimal tissue growth primarily at the proximal
edge (approximately 5.8%), and the E-SIRIUS trial re-
ported an in-segment restenosis rate of 5.9% with an almost
equal contribution of both stent edges (approximately
2.5%). The IVUS substudy of the E-SIRIUS trial aimed to
evaluate the EVR with a less-traumatizing implantation
technique (direct stenting and only selective post-dilation)
and demonstrated at 8 months no edge LL or vessel
remodeling at either SES edge. The findings of this study
highlighted the significant role of peri-procedural implan-
tation factors of GM (axial or longitudinal) in the occur-
Figure 1. EVR Assessment Through Evolution of PCI
The edge vascular response assessment through the evolution of Percutaneou
sound; OCT  optical coherence tomography; PCI  percutaneous coronary inrence of the EVR (25–27).The clinical importance of GM was further shown with
the STLLR study (Impact of Stent deployment Techniques
on cLinicaL outcomes of patients treated with the cypheR
stent), a multicenter prospective study that included patients
with native CAD treated with an SES. Target vessel
revascularization rates at 1 year were 59% higher in the GM
group compared with the non-GM group, mostly due to
longitudinal GM visible with a focal pattern of restenosis
mainly located at the proximal and distal SES edges (20)
(Table 1).
PACLITAXEL-ELUTING METALLIC PLATFORM. The ASPECT
trial (ASian Paclitaxel-Eluting Stent Clinical Trial) ran-
domized 81 patients to a BMS (n  25), a low-dose
olymer-free paclitaxel-eluting stent (PES) (n  28), or a
igh-dose polymer-free PES (n  28). Results indicated
hat there was no notable LL at 6 months at either stent
dge; however, no formal report was disclosed (28).
In the first-in-man TAXUS I trial (Comparison Among
Paclitaxel Eluting Stent Versus an Uncoated Bare Metal
tent), no edge effect was demonstrated with the slow
elease polymer formulation of the PES. Conversely, in the
AXUS II trial the slow release and moderate release
olymer formulations of the PES (Boston Scientific Cor-
oration, Natick, Massachusetts) resulted in a proximal edge
L of 0.54 2.1 mm2 and 0.88  1.9 mm2, respectively, at
-month FU, whereas the moderate release paclitaxel-
luting platform demonstrated an LL of only 0.19  1.7
m2 at the distal edge (29,30). Although the plaque
increased significantly at the edges of both devices, there
nary Intervention. EVR  edge vascular response; IVUS  intravascular ultra-
tion; VH  virtual histology.s Corowere no compensative changes in the external elastic lamina.
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214The TAXUS IV, V, and VI trials were prospective
randomized studies comparing the outcomes of PES
(TAXUS Express) versus BMS (Express) over a 9-month
imaging FU. In the TAXUS group, a decrease of the plaque
area comparable to the BMS was documented at the
proximal edge, whereas a combination of plaque progression
with constrictive remodeling led to significant LL, notably
in the 4- to 5-mm distal subsegments, at the distal edge
Table 1. Edge Vascular Response With 1st- and 2nd-Generation Drug-Elutin
IVUS-Based Assessment
Sirolimus-
Eluting Platform Trial Follow-Up
First Author
(Ref. #s)
Vesse
(m
CYPHER ®
RAVEL Post to 6m Morice/Serruys
(22,23)
SIRIUS Post to 8m Moses/Popma
(10,25)
E-SIRIUS Post to 8m Hoffmann (27)
DIABETES Post to 9m Jiménez-
Quevedo
(34)
1
Paclitaxel-eluting
platform
TAXUS I Post to 6m Grube (29)
TAXUS ®
TAXUS II Post to 6m Serruys (30)
TAXUS IV, V,
VI
Post to 9m Weissman (31) 2
BETAX Post to 6m Garcia-Garcia
(32)
1
Everolimus-
eluting
platform
SPIRIT II Post to 6m/post
to 2y
Gogas (54,55) -/
XIENCE V ®
SPIRIT III
JAPAN
Post to 8m Shimohama
(41)
2
Zotarolimus-
eluting
platform
ENDEAVOR II Post to 8m Sakurai (44)
ENDEAVOR  ®
ENDEAVOR III Post to 8m Miyazawa (44)
ENDEAVOR IV Post to 8m Waseda (45) 2
Everolimus-
eluting
platform
ABSORB B1/
ABSORB B2
Post to 6m &
post to 1y
Gogas (53) 2
Absorb BVS®
ABSORB B1 Post to 2y Gogas (54,55)
Themethodology to assess the stent/scaffold edge and the target lesion revascularization (TLR) rate
outgrowth of a side branch (SB) with an opening of90° (1 quadrant)/cross-section was an exclusi
360° the stent edge was defined with this methodology; IVUS: intravascular ultrasound; m(31). Finally, in the BETAX (Beside TAXus) trial, whichused the Taxus Express DES, significant tissue composi-
tional changes were observed—which was largely a result of
an increase in the fibrofatty tissue component leading to
expansive remodeling at both stent edges after plaque area
increase (32) (Table 1).
In general, the TAXUS trials documented LL at the stent
edges, but the mechanistic interpretation of the different
nts and Bioresorbable Vascular Scaffolds
mal Edge Distal Edge
Methodology to Assess the Stent,
Scaffold Edge/TLR (%)
Lumen Area
(mm2)
Vessel
Area
Lumen
Area
- - - QCA/0% (22) IVUS: 5-mm adjacent,
360, SB/() (23)
2 - - QCA & IVUS: 5-mm adjacent/5.8%,
proximal edge & 3.1%, distal edge
- - - IVUS: 5-mm adjacent/2.5% proximal &
distal edges
1 1 - IVUS: 5-mm adjacent/()
- - - IVUS: 5-mm adjacent/0%
2 - 2 IVUS: ﬁve 1-mm adjacent, 360,
SB/ 3% proximal edge
2 - 2 IVUS: ﬁve 1-mm adjacent/()
- 1 - IVUS: ﬁve 1-mm adjacent, 360, SB/()
- 1/2 - IVUS: 5-mm adjacent, 360,
SB/2% distal edge
2 1 2 IVUS: 5-mm adjacent/()
ge effect No edge effect IVUS: 5 1-mm adjacent/()
ge effect No edge effect IVUS: 5-mm adjacent/()
2 2 - IVUS: 5-mm adjacent/()
-/- -/- -/- IVUS: 5-mm adjacent, 360,
SB/3% proximal edge
2 - - IVUS: 5-mm adjacent, 360,
SB/3% proximal edge
odemonstrated. The position of the arrows demonstrate either significant increase or decrease. The
rion for the analysis of the stent edge.
; post post-procedure; QCA quantitative coronary angiography.g Ste
Proxi
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m2)
-
-
-
-
-
2
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-
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215platforms with different drug release kinetics potentially
explains the diverse vascular response with PES.
EVR With First-Generation DES in Clinical Subsets
Diabetes mellitus. The initial report of risk factors associ-
ated with DES restenosis in patients treated during the first
unrestricted use of SES since its CE mark approval was
made by our group. In particular, diabetes mellitus was
implicated as one of the strongest risk factors (33).
The DIABETES (Diabetes and Sirolimus Eluting Stent)
trial was the first to investigate the EVR after implantation
of an SES in diabetic patients at 9-month FU. At the
proximal edge, significant expansive remodeling was seen (
EEM volume: 8.6  19 mm3, p  0.04) to compensate
for a mild degree of plaque volume increase with an increase
of lumen volume. At the distal edge a similar response was
observed, with plaque progression compensated by expan-
sive remodeling:  EEM:5.1 12 mm3, (p 0.04) (34).
The DiabeDES trial (Diabetes and Drug-Eluting Stent
intravascular ultrasound trial) randomized 74 diabetic pa-
tients to either an SES or PES. At 8 months, the SES arm
demonstrated different tissue reactions compared with pre-
vious observations in the DIABETES trial. Notably, the
EEM remained unchanged at both stent edges. A lumen area
increase of 0.4  1.22 mm2 (p  0.032) was observed only at
he distal edge, which was due to a trend toward significant
ecrease of the plaque area from 5.8 to 5.6 mm2 (35).
Diabetic patients have an aggressive form of atheroscle-
osis compared with non-diabetic persons with a higher risk
f target lesion revascularization (TLR) due to angiographic
estenosis. Although the DIABETES and DiabeDES trials
nvestigated the EVR after implantation of the same plat-
orm/drug at similar time points, the vascular response was
ot consistent, as plaque progression (DIABETES) or
egression (DiabeDES) was documented.
This constitutes another example of discordance between
nvestigations. Obviously, restenosis—in particular edge
estenosis—is a multifactorial phenomenon, with multiple
nd overlapping precipitating factors (Fig. 2). However, in
he present case, differences in platform, drug, and time
oint of investigation can reasonably be excluded as con-
ounding factors. In the absence of a detailed methodolog-
cal description, differences in assessment might be a sus-
ected cause of discordance in the results (36–38).
Acute myocardial infarction. Two studies have previously
nvestigated EVR in the setting of acute myocardial infarc-
ion. These studies were the Leiden MISSION and the
ORIZONS AMI trials (Harmonizing Outcomes with
evascularization and Stents in Acute Myocardial Infarc-
ion). The Leiden MISSION trial compared the EVR in 40
atients undergoing implantation of either a Cypher stent
n  20) or a BMS (n  20) up to 8 months FU. Thevessels treated with a Cypher DES demonstrated a signif- aicant reduction in lumen area at the proximal edge from 8.6
to 7.9 mm2, whereas at the distal edge a nonsignificant
umen gain from 6.5 to 6.7 mm2 was evident (39).
In the IVUS substudy of the HORIZONS AMI trial,
464 patients were randomized in a 3:1 manner to either the
TAXUS EXPRESS PES or the EXPRESS BMS. At
13-month FU, the proximal edge segment of the vessels
treated with a PES demonstrated an LL of 0.7 mm2,
because of plaque/media increase, whereas at the distal edge
a lesser degree of LL of 0.2 mm2 was observed after modest
plaque/media increase (40). In the clinical setting of acute
myocardial infarction a similar proximal EVR with some
degree of LL was evident that was, however, not translated
to a definite edge effect.
Second-Generation DES
Everolimus-eluting metallic platform. The EVR with the
ience V everolimus-eluting stent (Abbott Vascular, Santa
lara, California) was evaluated serially up to 8 months in
he SPIRIT III JAPAN registry (n  73) and the SPIRIT
II US (n  110) randomized trial (41). The SPIRIT III
JAPAN registry demonstrated a significant increase in the
EEM volume index (expansive remodeling) from 9.9  4.2
to 10.3  4.5 mm3/mm (p  0.04) at the distal edge
ithout any significant changes in the lumen or plaque
olumes. In the SPIRIT III US trial, at the same time point,
Figure 2. Global Overview of Precipitating Factors Responsible for EVR
The clinical consequences are stent failure, either stent restenosis or stent
thrombosis. EVR  edge vascular response; m-TOR  mammalian target of
rapamycin.significant reduction of the lumen volume index from 7.3 2.4
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216mm3/mm to 6.9  2.4 mm3/mm at the proximal edge was
evident (41).
The first serial assessment of the EVR after implantation
of the Xience V everolimus-eluting stent at 6-month and
2-year FU has recently been reported in the IVUS substudy
of the SPIRIT II trial (42). At the distal edge a significant
increase of the EEM (expansive remodeling) area was
evident ( EEM: 0.62 mm2 [0.22 to 1.27 mm2]) at 6
months, similar to the prior observation of the SPIRIT III
JAPAN registry; however, from 6 months to 2 years, a
different biological behavior became apparent as significant
constrictive remodeling ( EEM: 0.50 [1.19 to 0.14]
mm2) was observed within this segment. From 6 months to
2 years, a significant reduction of the EEM area was also
detected at the proximal edge, without significant lumen or
plaque changes.
It has been speculated that this constrictive remodeling is
potentially related to chronic alterations of the vascular
compliance at the transition zones between the scaffolded
and unscaffolded segments (43).
Zotarolimus-eluting metallic platform. The EVR with the
Endeavor zotarolimus-eluting stent (ZES) (Medtronic
Vascular, Santa Rosa, California) was reported in the
ENDEAVOR II (Randomized Controlled Trial to Eval-
uate the Safety and Efficacy of the Medtronic AVE
ABT-578 Eluting Driver Coronary Stent in De Novo
Native Coronary Artery Lesions) and III trials (A Ran-
domized Controlled Trial of the Medtronic Endeavor
Drug (ABT-578) Eluting Coronary Stent System Versus
the Cypher Sirolimus-Eluting Coronary Stent System in
De Novo Native Coronary Artery Lesions). These studies
compared serially up to 8-month FU the Endeavor ZES,
the Driver BMS, and the first-generation Cypher SES.
No edge effect was shown with the ZES either in the
ENDEAVOR II or ENDEAVOR III trials (44).
In the ENDEAVOR IV trial (Randomized Comparison of
Zotarolimus- and Paclitaxel-Eluting Stents in Patients with
Coronary Artery Disease) the EVR was investigated serially up
to 8 months with IVUS imaging. At the proximal edge, a
significant decrease of the lumen volume index of  0.4 1.0
m3/mm was evident, without signs of vessel remodeling.
At the distal edge, the lumen volume index was reduced
( 0.5  1.1 mm3/mm) after an almost significant
ncrease of the plaque volume ( 0.2  0.6 mm3/mm)
45) (Table 1).
Although the ENDEAVOR studies evaluated the same
evice platform with similar drug release kinetics at corre-
ponding imaging FU time points, the EVR was not
onsistent. Excluding the device-related factors as precipi-
ating components of the edge LL, we can only speculate
hat precipitating biological factors in association with
ethological inconsistencies explain this finding, becausehe latter information was not provided.essons Learned From an IVUS-Based Assessment
f the EVR With First-Generation DES
The EVR, with first-generation DES in simple lesions,
complex populations, and specific clinical subsets, demon-
strated in most studies proximal edge LL that caused
clinical restenosis (TLR) or edge effect (diameter stenosis
50%) in only a small percentage of cases. Proximal edge
LL, however, was not shown with all studies. The explana-
tions for this variance in the vascular responses at the edges
are: 1) the mechanism of the EVR with its multifactorial
etiology; and 2) potential methodological inconsistencies
related to technical guidelines.
Three major implicated factors predispose to an abnormal
EVR: 1) iatrogenic factors, related to the periprocedural
GM, axial or longitudinal; 2) device factors, associated with
the type of the implanted device (metallic or polymeric),
device-induced edge dissections, type/release kinetics of the
anti-proliferative drug (mammalian target of rapamycin
inhibitor or paclitaxel or actinomycin), and phenomenon of
drug resistance; and 3) biological factors mainly linked to
the remaining plaque burden and necrotic core tissue at the
edges when the “normal to normal” landing of the device
has not been achieved.
Specific technical guidelines implemented by our group
(Cardialysis BV, Rotterdam, the Netherlands) have been
implemented by our group for the analysis of the EVR with
first- and second-generation DES and bioresorbable devices
(46). In particular, stent edge is defined as the first cross-
section exhibiting visible struts in a circumference of360°.
The first and last cross-sections with visible struts in a
circumference of 360° are defined as the stented segment
(Fig. 3, Table 1). The rationale for this methodological
approach is based on prior observations showing that the
motorized IVUS pullback (0.5 mm/s) is highly affected by
cardiac motion (systole/diastole) causing a longitudinal
displacement of the IVUS transducer between systole and
diastole of 1.5 0.80 mm (range from 0.5 to 5.5 mm). This
phenomenon known as the “scrambling effect” makes it difficult to
sharply define the exact location of the stent edge (47). Although
electrocardiogram-gated IVUS acquisition by selecting near-
end diastolic frames can reduce motion-induced artefacts,
this does not fully prevent the imaging of stent struts over
the transition zones (48 –50).
These technical limitations are potential confounding
factors that alter the precise EVR assessment with IVUS-
based imaging. Novel imaging modalities with higher spa-
tial resolution and lesser motion-induced artefacts, such as
OCT, have recently been investigated to assess the EVR.
OCT-Based Assessment of the EVR
Although sound-based imaging was until recently the sole
intravascular imaging modality for the EVR assessment, this
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217technique seems to have some limitations. Thus, our group
has explored the EVR evaluation with light-based imaging,
such as OCT. Despite the low penetration depth of this
imaging technique—which limits the precise assessment of
the EEM (vessel area) making it difficult to assess vessel
remodeling—the sharply defined stent edges makes this
imaging tool an alternative modality to evaluate the changes
in lumen area and superficial plaque composition with a
near-histological spatial resolution (51,52).
The methodology to assess the OCT-derived stent edge
is similar to the previously IVUS-derived definition; how-
ever, the fast pullback speed of 20 to 40 mm/s compared
with the 0.5 mm/s of IVUS detects the demarcation of the
stent/scaffold edges more categorically.
The first OCT-based EVR assessment was performed in
the ABSORB Cohort B [NCT00856856] trial (n  101).
The ABSORB Cohort B1 (n  45) underwent intracoronary
ulti-imaging assessment at post-procedure, 6 months, and 2
ears, whereas the ABSORB Cohort B2 (n  56) underwent
OCT assessment at post-procedure 1 year and is currently
undergoing a 3-year imaging assessment. In Cohort B1, 16
roximal and 18 distal edge segments were available for a serial
nalysis with OCT. There was no LL at either the proximal or
Figure 3. IVUS-Based and OCT-Based Assessment of EVR
(A) Demonstrates the last frame with visible struts in a circumference of 360°
(presence of the scrambling effect) and OCT (absence of scrambling effect). In
ance of the struts in the cross-section deﬁned as stent edge. Dist  distal; PBistal scaffold edges. However, in Cohort B2 where 20 proxi- bmal and distal edge segments were serially assessed post-
procedure and at 1 year, an LL of 0.50  1.79 mm2 (p 
0.012) was observed at the proximal scaffold edge (Online
Table 1).
The TROFI trial [NCT01271361] is the second OCT-
based study in which the EVR was assessed in the setting of
acute myocardial infarction after implantation of the Nobori
(Terumo, Europe NV, Leuven, Belgium) metallic stent at
6-month FU.
Thirty-five proximal and 46 distal edge segments were
analyzed serially, post-procedure, and at 6-month FU. At
both edges a significant LL became evident. In particular,
an LL of 0.52 1.19 mm2 (p 0.001) was measured at the
proximal edge, whereas at the distal edge a lesser degree of
LL was shown (0.40  1.17 mm2, p  0.015) (Online
able 1). The OCT-based assessment of the EVR in these
ilot studies shows proximal edge LL; however, larger
ohorts are needed to validate these preliminary results.
VR With Bioresorbable Scaffolds
EVR with the Absorb bioresorbable vascular scaffold. The
bsorb bioresorbable vascular scaffold (Absorb BVS) (Ab-
oth imaging modalities. (B to F) Demonstrate the difference between IVUS
ast to IVUS, OCT demarcates the edge sharply with the sudden disappear-
lback; Prox  proximal; other abbreviations as in Figure 1.with b
contrott Vascular) has been evaluated within the ABSORB
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218Cohort A trial (A Clinical Evaluation of the Bioabsorbable
Vascular Solutions Everolimus Eluting Coronary Stent
System in the Treatment of Patients With Single de Novo
Native Coronary Artery Lesions) up to 5 years and the
ABSORB Cohort B trial up to 2 years. In total, 101 patients
were enrolled, which were further divided to 2 subgroups—
Cohort B1 (n 45), and Cohort B2 (n 56)—according to
he predefined study design [NCT00300131]. The non-
erial IVUS-based evaluation of the EVR at 6 months in
ohort B1 demonstrated some degree of constrictive re-
modeling at the proximal edge:  EEM 1.80% [3.18%
to 1.30%], p  0.05, which was similar to that previously
een with metallic stents at the same time point; however,
his response was less evident in Cohort B2 at 1 year: 
EEM: 1.53% [7.74% to 2.48%], p  0.06 (53).
The serial evaluation of Cohort B1 at 2 years (from
post-procedure to 2 years) revealed a significant LL of 0.53
(1.22 to 0.18) mm2 with a trend toward plaque area
ncrease of 0.48 (0.25 to 1.03) mm2 (p  0.06) at the
proximal edge. In addition, distal edge changes in tissue
composition became evident with a significant increase of
the fibrofatty tissue component from 0.09 (0.04 to 0.22)
mm2 to 0.22 (0.14 to 0.51) mm2 and a percentile increase of
68.37% (17.82% to 171.17%) (p  0.013) (54,55).
Although the ischemia-driven TLR rate in the ABSORB
ohort B trial at 1 year was as low as 4%, 2 of the TLR cases
ere attributed to a proximal edge effect related to iatro-
enic factors and more in particular to longitudinal GM. At
years, the ischemia-driven TLR rate remained low (6%)
ithout new episodes of exuberant EVR.
The 2-year imaging FU with the Absorb BVS for the
ssessment of the EVR is the longest available in the
ublished data. Similar studies using the upcoming biore-
orbable scaffold technologies at the same time point—such
s the drug-eluting absorbable metal scaffold (DREAMS)
Biotronik, Bülach, Switzerland); the ReZolve Sirolimus-
luting Bioresorbable Coronary Scaffold (REVA Medical,
an Diego, California); and the Ideal Biostent (Xenogenics
orporation, Philadelphia, Pennsylvania) (the second-
eneration BTI stent [BTI, Menlo Park, California]), made
f magnesium, tyrosine polycarbonate, and salicylic acid,
espectively—are expected to establish the potential dy-
amic behavior of the transient scaffolds at the edges,
ompared with the permanent metallic stents.
The EVR up to 2 years with a fully bioresorbable device
emonstrates LL at the proximal edge that results in clinical
estenosis or edge effect in 6% of cases and tissue com-
osition changes at the distal edge.
linical Implications of EVR
The EVR pathophysiology has been scrutinized and shown
to be of multifactorial origin rather than a single etiology. It
is the interplay among several factors: 1) peri-procedural; 2)device-related; and 3) biological factors resulting in either
device restenosis or ST (Fig. 2). The EVR in the current
interventional practice with second-generation DES and in
the future with bioresorbable devices will further reduce the
incidence of edge effect and the subsequent need for TLR.
The implantation of metallic devices has been previously
shown to cause alterations in 3-dimensional vessel geometry
and induce compliance mismatch between the stented part
of the artery and its upstream and downstream segments as
assessed in preclinical models and human arteries (56,57).
Additionally, diameter mismatch after stent implantation
between the stented segment and the native artery (axial
GM/over-dilation) might cause step-up regions at the
transition zones with subsequent disturbance of the laminar
flow and induction of flow separation and retrograde axial
velocities (58). These effects induce local wall shear stress
alterations at the stented segments and the transition zones,
resulting in tissue growth and potentially restenosis. How-
ever, 2 fundamental technical aspects of deployment have
been appreciated by the interventional community: 1) the
optimal device deployment: avoidance of overstretching
during the culprit lesion preparation, and the use of balloons
shorter than the implanted device during pre- or post-
dilation; and 2) the importance of the healthy “landing
zone” (normal to normal) of the device during stenting.
Recent studies using VH-IVUS imaging have shown that
the site of the plaque rupture is more likely to be located at
the proximal edge of the plaque (43.7%) rather than the site
of the minimum lumen area (25.6%), and the longitudinal
distribution of the largest necrotic core is more often at the
proximal edge of the plaque rather than at the minimum lumen
area (59,60). In the European Collaborative Project on Inflam-
mation and Vascular Wall Remodeling in Atherosclerosis -
Intravascular Ultrasound Study (AtheroRemoIVUS) trial it
was demonstrated that the landing of a device in a VH-IVUS–
defined thin cap fibroatheroma (vulnerable plaque) reaches the
rate of approximately 11% (61), whereas in the BETAX study
necrotic core rich areas were left un-stented: proximal edge
17% (13.5%), and distal edge 18.5% (16.5%), with no reported
episodes of ST during the 6-month FU (32).
It is important that these necrotic core rich lesions at the
stent edges are covered with a small neointimal layer; the
latter has been assessed in 80 patients where the long-term
native artery vascular responses (median 10 months) after
76 DES implantations compared with 32 BMS were
evaluated by VH-IVUS. The incidence of necrotic core
abutting the lumen within the adjacent reference segments
decreased in the BMS-treated lesions (proximal 23% to 0%;
distal 21% to 0%) but not in the DES-treated lesions (proximal
22% to 17%; distal 23% to 21%) (62). As a consequence, the
normal to normal coverage of the culprit lesion is a mandatory
approach for the interventionalist to avoid potential definite,
probable, or possible ST (according to the Academic Research
Consortium definition) (32,33,63,64).
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219Vasomotor dysfunction at the proximal and distal stent
edges after implantation of first-generation DES has been
reported to be associated with delayed vascular healing and
impaired endothelialization, potentially caused by polymer-
induced inflammation, drug toxicity, and hypersensitivity
reactions with eosinophilic infiltrations. These pathological
findings have been associated with increased risk of late and
very late ST (1,65–69). Meanwhile, the advent of new
devices with either bioresorbable polymers or bioresorbable
platforms have shown restoration of vasomotor function at
the device edges and might potentially eliminate the risk of
ST arising from the transition zones (70,71).
Edge dissections after implantation of metallic devices have
been previously associated with events of early ST. The
incidence of OCT-detected edge dissections has been reported
to be as high as 34%, compared with 19.3% of IVUS-detected
dissections. Most dissection flaps heal with only a minority of
patients experiencing clinical adverse events (72,73).
An exuberant EVR in the setting of a post-procedural
dissection has been shown to be associated with the flap length.
We have recently demonstrated the first OCT-based assess-
ment of such an exuberant EVR implantation of a metallic
device attributed to a large post-procedural dissection flap
originating deep in the media, causing edge restenosis (74).
he incidence of dissections at the transition zones of biore-
orbable devices has not been investigated yet; meanwhile, this
s expected to be rather low, because most of the treated lesions
n the first-in-man studies were Type A.
Finally, the development of in-stent neoatherosclerosis with
MS and first-generation DES has been proposed as another
are contributing factor for episodes of ST (75). Lee et al. (76)
emonstrated by IVUS that BMS implantation was associated
ith events of very late ST, because of disease progression and
eoatherosclerotic plaque rupture, in contrast to DES where
T appeared earlier and was mainly associated with stent
alapposition. More recently, similar findings were shown
rom thrombectomy specimens extracted from patients who
resented with definite ST after BMS implantation. Disrup-
ion of de novo atherosclerotic plaques in stented segments and
he proximal and distal edges were attributed as the main
echanism for the acute event (77,78).
Since the era of vascular brachytherapy, the ABSORB
ohort B and BETAX studies were the only studies that
nvestigated tissue composition changes at the edges with
H-IVUS imaging. Although different drug-eluting plat-
orms were used at various time points, both studies
emonstrated an increase of the fibrofatty tissue component
t 6-month FU. Adaptive expansive remodeling of the
essel treated with the TAXUS Express (from 6.2 to 7.7
m2) was observed as well as nonsignificant adaptive
expansion of the vessel treated with the Absorb BVS
(3.45%). Fibrofatty tissue is a surrogate marker of extracel-
lular matrix production, consisting of proteoglycans, hyalu-ronan, and collagen (Type I and III) implicated for neoin-
timal growth and remodeling (79).
Drug-eluting bioresorbable scaffolds with properties that
allow for the repair of the treated vessel rather than
permanent caging (vascular reparative therapy) have shown,
both with IVUS and OCT, proximal edge LL at the transition
zones up to 2 years. The upcoming 3-year imaging FU of the
scaffold edges will help to unravel the ultimate state of EVR.
At this time the polymer will have been replaced by connective
tissue integrated with the vessel wall and will potentially help
clarify the dynamic nature of the initially observed vascular
response at the scaffold edges (80).
Conclusions
Edge vascular response has been observed with BMS,
radioactive stenting, DES, and bioresorbable devices, dem-
onstrating—in most studies—proximal edge LL that causes
clinical restenosis or edge effect in a minority of cases. The
advent of light-based imaging with its ultra-high spatial
resolution is expected to improve the in vivo assessment of
the EVR especially in those cases in which ST due to edge
disease has devastating consequences.
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